Featured New Tests
Unique New Test for Liver Fibrosis
FibroMeter VCTE is a unique laboratory test that combines biomarkers and a liver stiffness measurement by FibroScan to provide enhanced classification accuracy for patients with chronic hepatitis B or C (with or without HIV co-infection), or patients with non-alcoholic fatty liver disease (NAFLD).Details
|3001379||FibroMeter Vibration Controlled Transient Elastography (FibroMeter plus FibroScan VCTE)|
- Enhanced classification accuracy
- First integrated patient report combining the FibroScan liver stiffness measurement and FibroMeter results
See test details, order info, and educational resources for FibroMeter VCTE.
Newborn Drug Detection Panel Now Includes Gabapentin
Detect gabapentin in umbilical cord tissue and provide the best care for your newborns. ARUP is the only lab offering umbilical cord tissue for gabapentin, helping you increase the accuracy and speed with which you treat newborns.Details
|2006621||Drug Detection Panel, Umbilical Cord Tissue|
ARUP’s neonatal drug testing in umbilical cord tissue is based on highly sensitive and specific qualitative liquid chromatography and tandem mass spectrometry (LC-MS/MS). This test can help with timely detection of in utero drug exposure.
ARUP's comprehensive newborn drug testing services includes meconium testing, drugs and drug metabolites, and educational resources.
Prostate Health Index: A More Precise Cancer Screening Test
This FDA-approved test for prostate cancer screening is a multi-analyte blood test that improves the interpretation of an elevated PSA level.
Using an algorithm that calculates the results of three tests into one score, the results provide a more accurate diagnostic evaluation for determining which patients should proceed to biopsy.Details
|3000134||Prostate Health Index|
- Recommended in the National Comprehensive Cancer Network (NCCN) guidelines for prostate cancer early detection.
- In a multicenter study of men with PSA levels between 4 and 10 ng/mL, the Prostate Health Index test was shown to outperform free and total PSA for prostate cancer detection.1
- New York State Department of Health approved.
1 Loeb S, Catalona WJ: The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol 2014 Apr;6(2):74-77.
Secondary Diagnostic For Generalized or Ocular Myasthenia Gravis
Designed for patients with generalized or ocular myasthenia gravis and no detectable antibodies to acetylcholine receptor (AChR).Details
|3001576||Muscle-Specific Kinase (MuSK) Antibody, IgG|
This secondary diagnostic test can help clinicians guide treatment, as decreasing antibody levels may be associated with therapeutic response. A negative test result does not rule out a diagnosis of myasthenia gravis.
Diagnosing CNS Demyelinating Disease or Autoimmune Encephalitis
Useful for initial evaluation of inflammatory CNS demyelinating disease, including neuromyelitis optica spectrum disorder (NMOSD) and NMOSD-like disorders, or autoimmune encephalitis.Details
|3001277||Myelin Oligodendrocyte Glycoprotein (MOG) Antibody, IgG by IFA with Reflex to Titer, Serum|
|3001283||Autoimmune CNS Demyelinating Disease Reflexive Panel|
The presence of myelin oligodendrocyte glycoprotein (MOG) antibody may be associated with neuromyelitis optica spectrum disorders, including optic neuritis and transverse myelitis, brainstem encephalitis, and acute disseminated encephalomyelitis.
This test may be used in monitoring antibody persistence or treatment response in individuals who are antibody positive.
New Oncology Tests: Lymphomas and IHC StainsDetails
|3001568||IRF4/DUSP22 (6p25) Gene Rearrangement by FISH|
Used to detect IRF4/DUSP22 rearrangements that can contribute to diagnosis and prognosis in B-cell and T-cell lymphomas.
|3001697||Carbonic Anhydrase IX|
Updated Pharmacogenetic Tests
Pharmacogenetic testing assesses the risk of abnormal drug metabolism for medications metabolized in specific metabolic pathways.
ARUP has updated our pharmacogenetic tests with new medically relevant genes and variants in our panels.Details
|3001524||Cytochrome P450 Genotyping Panel|
|3001501||CYP2C8 and CYP2C9|
|3001518||CYP3A4 and CYP3A5|
|3001535||TPMT and NUDT15|
|3001541||Warfarin Sensitivity (CYP2C8, CYP2C9, CYP4F2, VKORC1) Genotyping|
Pharmacogenetic testing provides an opportunity to lower the cost of adverse drug events by:
- Preventing many adverse drug events before they occur.
- Reducing pharmacy costs for clients by optimizing dosage.
- Decreasing the number of patient hospitalizations.
- Improving patient compliance with their drug therapies.
Learn more about ARUP's pharmacogenetics testing, including cost savings, educational resources, and full test list.